Polymorphism in the oxytocin promoter region in patients with lactase non-persistence is not related to symptoms.

Truedsson M, Carlson J, Simrén M, Ohlsson B

BMC gastroenterology30 Nov 2009Cited by 5 (Europe PMC)

PMID19943975PMCIDPMC2789731DOI10.1186/1471-230x-9-90PepBankPUB-19943975

Summary

BackgroundOxytocin and the oxytocin receptor have been demonstrated in the gastrointestinal (GI) tract and have been shown to exert physiological effects on gut motility. The role for oxytocin in the pathophysiology of GI complaints is unknown. The aim of this study was to examine genetic variations or polymorphism of oxytocin (OXT) and its receptor (OXTR) genes in patients with GI complaints without visible organic abnormalities.MethodsGenetic variants in the OXT promoter region, and in the OXTR gene in DNA samples from 131 rigorously evaluated patients with Irritable Bowel Syndrome (IBS), 408 homozygous subjects referred for lactase (LCT-13910 C>T, rs4988235) genotyping, and 299 asymptomatic blood donors were compared. One polymorphism related to the OXT gene (rs6133010 A>G) and 4 related to the OXTR gene (rs1465386 G>T, rs3806675 G>A, rs968389 A>G, rs1042778 G>T) were selected for genotyping using Applied Biosystems 7900 HT allele discrimination assays.ResultsThere were no statistically significant differences in the genotype or allele frequencies in any of the SNPs when IBS patients were compared to healthy controls. Among subjects referred for lactase genotyping, the rs6133010 A>G OXT promoter A/G genotype tended to be more common in the 154 non-persistent (27.3%) subjects than in the 254 lactase persistant (18.1%) subjects and in the healthy controls (19.4%) (p = 0.08). When direct comparing, the A/G genotype was less common in the OXT promoter region in controls (p = 0.09) and in subjects with lactase persistence (p = 0.03) compared to subjects with lactase non-persistence. When healthy controls were viewed according to their own LCT-13910 genotypes, the C/C lactase non-persistent controls had a higher frequency for the OXT promoter A/G genotype than LCT-13910 T/T lactase persistent controls (41.2% vs 13.1%).No significant differences in frequencies of the investigated OXTR SNPs were noted in this study.ConclusionThe results suggest that polymorphism in the promoter region of the OXT gene is most common in subjects with lactase non-persistence. This polymorphism may not be related to GI symptoms, as it is related to lactase non-persistence also in healthy controls.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

01HumanNot a test of Oxytocin aloneObservational studyOther
In patients with irritable bowel syndrome, genotype and allele frequencies of the studied OXT and OXTR variants did not differ from healthy controls.
In plain wordsIn people with irritable bowel syndrome, oxytocin gene variants were not more common than in healthy controls.
Peptide
Oxytocin
Outcome
No significant changeOXT and OXTR genotype and allele frequencies in IBS
Study
n: not reported in source
Comparator
Healthy controls
Outcome group
Genetic association · Gastrointestinal
Source sentences
Summary
There were no statistically significant differences in the genotype or allele frequencies in any of the SNPs when IBS patients were compared to healthy controls.
1 context sentence(design, population, supporting numbers)
Summary · context
Genetic variants in the OXT promoter region, and in the OXTR gene in DNA samples from 131 rigorously evaluated patients with Irritable Bowel Syndrome (IBS), 408 homozygous subjects referred for lactase (LCT-13910 C>T, rs4988235) genotyping, and 299 asymptomatic blood donors were compared.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Show in the study text Report a problemFND-1994397501
02HumanNot a test of Oxytocin aloneObservational studyOther
The OXT promoter A/G genotype tended to be more common in lactase non-persistent subjects than in lactase persistent subjects and controls, not significantly.
In plain wordsAn oxytocin gene variant tended to be more common in people with lactase non-persistence, but the difference was not significant.
Peptide
Oxytocin
Outcome
No significant changeOXT promoter A/G genotype in lactase non-persistence
Study
n: not reported in source
Comparator
Lactase persistent subjects and healthy controls
Outcome group
Genetic association · Gastrointestinal
Measurements
A/G genotype frequency
27.3%
lactase non-persistent
A/G genotype frequency
18.1%
lactase persistent
A/G genotype frequency
19.4%
healthy controls
Source sentences
Summary
Among subjects referred for lactase genotyping, the rs6133010 A>G OXT promoter A/G genotype tended to be more common in the 154 non-persistent (27.3%) subjects than in the 254 lactase persistant (18.1%) subjects and in the healthy controls (19.4%) (p = 0.08).
1 context sentence(design, population, supporting numbers)
Summary · context
Genetic variants in the OXT promoter region, and in the OXTR gene in DNA samples from 131 rigorously evaluated patients with Irritable Bowel Syndrome (IBS), 408 homozygous subjects referred for lactase (LCT-13910 C>T, rs4988235) genotyping, and 299 asymptomatic blood donors were compared.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Show in the study text Report a problemFND-1994397502
03HumanNot a test of Oxytocin aloneObservational studyOther
The OXT promoter A/G genotype was less common in subjects with lactase persistence than in subjects with lactase non-persistence.
In plain wordsAn oxytocin gene variant was less common in people with lactase persistence than in people with lactase non-persistence.
Peptide
Oxytocin
Outcome
Not applicableOXT promoter A/G genotype in lactase persistence versus non-persistence
Study
n: not reported in source
Comparator
Lactase non-persistent subjects
Outcome group
Genetic association · Gastrointestinal
Source sentences
Summary
When direct comparing, the A/G genotype was less common in the OXT promoter region in controls (p = 0.09) and in subjects with lactase persistence (p = 0.03) compared to subjects with lactase non-persistence.
1 context sentence(design, population, supporting numbers)
Summary · context
Genetic variants in the OXT promoter region, and in the OXTR gene in DNA samples from 131 rigorously evaluated patients with Irritable Bowel Syndrome (IBS), 408 homozygous subjects referred for lactase (LCT-13910 C>T, rs4988235) genotyping, and 299 asymptomatic blood donors were compared.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Show in the study text Report a problemFND-1994397503
04HumanNot a test of Oxytocin aloneObservational studyOther
Among healthy controls, the OXT promoter A/G genotype was more frequent in C/C lactase non-persistent controls than in T/T lactase persistent controls.
In plain wordsIn healthy people, an oxytocin gene variant was more common in those with lactase non-persistence genotypes than in those with persistence genotypes.
Peptide
Oxytocin
Outcome
Not applicableOXT promoter A/G genotype by LCT-13910 genotype in healthy controls
Study
n: not reported in source
Comparator
LCT-13910 T/T lactase persistent controls
Outcome group
Genetic association · Gastrointestinal
Measurements
A/G genotype frequency
41.2%
C/C lactase non-persistent controls
A/G genotype frequency
13.1%
T/T lactase persistent controls
Source sentences
Summary
When healthy controls were viewed according to their own LCT-13910 genotypes, the C/C lactase non-persistent controls had a higher frequency for the OXT promoter A/G genotype than LCT-13910 T/T lactase persistent controls (41.2% vs 13.1%)
1 context sentence(design, population, supporting numbers)
Summary · context
Genetic variants in the OXT promoter region, and in the OXTR gene in DNA samples from 131 rigorously evaluated patients with Irritable Bowel Syndrome (IBS), 408 homozygous subjects referred for lactase (LCT-13910 C>T, rs4988235) genotyping, and 299 asymptomatic blood donors were compared.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Show in the study text Report a problemFND-1994397504
05HumanNot a test of Oxytocin aloneObservational studyOther
No significant differences were noted in the frequencies of the investigated OXTR variants.
In plain wordsNo significant differences were found in oxytocin receptor gene variants between the groups.
Peptide
Oxytocin
Outcome
No significant changeOXTR SNP frequencies
Study
n: not reported in source
Outcome group
Genetic association · Gastrointestinal
Source sentences
Summary
No significant differences in frequencies of the investigated OXTR SNPs were noted in this study.
1 context sentence(design, population, supporting numbers)
Summary · context
Genetic variants in the OXT promoter region, and in the OXTR gene in DNA samples from 131 rigorously evaluated patients with Irritable Bowel Syndrome (IBS), 408 homozygous subjects referred for lactase (LCT-13910 C>T, rs4988235) genotyping, and 299 asymptomatic blood donors were compared.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Show in the study text Report a problemFND-1994397505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 01:30 UTC
Study results updated
Version 1
9 Oct 2026, 02:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.